Novavax, Inc. (NVAX) — closed signal from March 14, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 12, 2026.
Predicted vs. what happened
NVAX price · publication thesis → realized outcomesplit-adjusted
$9.70 – $10.50Entry zone — fair-value band
$10.24Published — price the day we called it
$12.49Target — the price the thesis aimed for
$11.61Peak — highest point inside the window, not a realized return
$8.88Window close — end-of-window price, context only
What happened
Partial
Reached 61% of the predicted growth at its peak, without hitting the target.
Peak price
$11.61
peak on May 27, 2026 — not a realized returnPeak gain
+13.4%
peak, from the publication priceWindow close
$8.88
end-of-window price, context onlyDays to target
—
Window
March 14, 2026 – June 12, 2026
The thesis — published March 14, 2026
Predicted growth
+22%
over the measurement windowTarget price
$12.49
the price the thesis aimed forEntry zone
$9.70 – $10.50
the fair-value band we waited forPrice at publication
$10.24
published March 14, 2026Confidence
85%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novavax went from being mostly a hope story to showing real business progress: it unexpectedly made a profit and signed a licensing deal with Pfizer. That outside deal and better recent results make a near-term rebound more believable. The stock is still risky and can move fast, so keep positions small and manage risk.
Primary drivers
- Unexpected profit made the business story stronger
- Pfizer deal gives outside validation for the company
- Licensing expands where the company can earn money
- Price movement now matches improving business news
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.